Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART30 in CD30+ Lymphomas
NCT02259556Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2014
- Primary completion
- Oct 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CART30 in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by Chinese PLA General Hospital. Started Oct 2014; status: recruiting.
02
Drugs
CART30
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02259556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259556.